Penn Nobel-Prize Winners Receive Warm Welcome in Sweden
Karikó and Weissman were celebrated at several days of ceremonies and festivities in Sweden, two months after first learning the news.
Penn Engineering’s Miskin Lab Featured on CNN for Origami Inspired Microrobots that Could Repair Nerves
The goal of this innovative technology is to use the microrobots to assist in repairing peripheral nerves.
More than 260,000 Penn Medicine patients have agreed to share their DNA for research via Penn Medicine BioBank
By obtaining samples from a wide-cross section of humanity, researchers are able to cross-reference participants’ DNA with their health records and identify genetic variants for a range of diseases.
Long-term Penn Research Across Disciplines Leads to the Development of a New ‘Patch’ that Uses Natural Body Motion to Fix Disc Herniation
A new biologic “patch” that is activated by a person’s natural motion has the potential to fix herniated discs in people’s backs, according to researchers at Penn Medicine and the CMC VA Medical Cente
Carisma Therapeutics Receives FDA Clearance of Investigational New Drug Application for CT-0525, a Novel CAR-M Cell Therapy
Having received a Study May Proceed notification from the FDA, Carisma plans to initiate a Phase 1 study in the months to come and to treat the first patient in the first half of 2024.
Penn’s Role in Philadelphia’s Rapidly Growing Life Sciences Industry
Technical.ly published an article about the future of the growth of the life sciences in Philadelphia, highlighting Penn’s role in the development of the city as a strong tech hub.
Gov. Josh Shapiro, President Liz Magill, and others from the Penn community Celebrate the new Penn Institute for RNA Innovation
“One of our great strategic advantages is our compact and contiguous campus, where 12 amazing schools and a world-class health system coexist just a short walk from one another,” said Magill.
Mitchell Lab: Lipid nanoparticles that deliver mRNA to T cells show potential treatment for autoimmune diseases
The goal of this platform is to engineer adoptive cell therapies inside of the body for specific autoimmune diseases.
Cabaletta Bio Receives Another FDA Clearance for IND application of CABA-201
The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients with generalized myasthenia gravis (gMG).
First canine patient receives Vetigenics’ fully canine anti-CTLA4 monoclonal antibody
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.